This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2022
  • /
  • 11
  • /
  • Alkermes plc announces intent to separate oncology...

Alkermes plc announces intent to separate oncology business.

Read time: 1 mins
Published:3rd Nov 2022

Alkermes plc announced approval by its Board of Directors to explore separating its commercial-stage neuroscience business and development-stage oncology business

The company, together with the Board and external financial and legal advisors, plans to explore a separation of the oncology business into an independent, publicly-traded company (Oncology Co.) as part of an ongoing review of strategic alternatives for the oncology business.

Alkermes believes separation of the oncology business into Oncology Co. would: i. Drive a sharp strategic focus for each business; ii. Establish separate and distinct management teams with relevant therapeutic expertise based on each business' unique strategic priorities and opportunities; iii. Simplify capital allocation decision-making and increase flexibility to pursue growth and investment strategies more directly aligned with each business' respective goals; and iv. Enable the capital markets to better assess each business' value, performance and potential, and attract a long-term shareholder base suited to each business.

Condition: Mucosal Melanoma
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.